Table 1.
Patients and samples
| Anti-TIF1γ-positive | Anti-TIF1γ-negative | Total | |||
|---|---|---|---|---|---|
| CAM | Non-CAM | CAM | Non-CAM | ||
| Total number of patients, n (%) | 15 (65) | 8 (35) | 6 (20) | 24 (80) | 53 |
| Paired tumour/blood DNA, n | 7 | – | 3 | 3 | 13 |
| Mean germline TIF1 events | 7.9 | – | 8.3 | 6.7 | |
| Somatic mutations (SM) of TIF1, n (%) | 1 (14) | – | 0 (0) | 0 (0) | 1 |
| Patients with LOHa, n (%) | 5 (71) | – | 1 (33) | 0 (0) | 6 |
| TIF1γ (TRIM33), n (%) | 1 (14) | – | 1 (33) | 0 (0) | 2 |
| TIF1α (TRIM24), n (%) | 2 (29) | – | 0 (0) | 0 (0) | 2 |
| TIF1β (TRIM28), n (%) | 1 (14) | – | 0 (0) | 0 (0) | 1 |
| TIF1δ (TRIM66), n (%) | 2 (29) | – | 0 (0) | 0 (0) | 2 |
| Patients with SM or LOH, n (%) | 6 (86) | – | 1 (33) | 0 (0) | 7 |
| TIF1γ staining, mean (s.d.) | |||||
| Myositis patient tumour | 255 (56) | – | 251 (49) | 140 (113) | 243 (66) |
| Paired control tumour | 196 (33) | – | 152 (99) | 190 (0) | 183 (59) |
| Muscle | 37.3 (15.9) | 9.5 (23.3) | – | 4.9 (7.3) | 10 (26) |
| Skin | 300 (0) | – | 300 (0) | – | 300 (0) |
a
LOH in two TIF1 genes (TIF1α and TIF1β) was detected in the samples of one patient.